NO20045245L - Anvendelse av valsartan eller dens metabolitt for a inhibere blodplateaggregering - Google Patents
Anvendelse av valsartan eller dens metabolitt for a inhibere blodplateaggregeringInfo
- Publication number
- NO20045245L NO20045245L NO20045245A NO20045245A NO20045245L NO 20045245 L NO20045245 L NO 20045245L NO 20045245 A NO20045245 A NO 20045245A NO 20045245 A NO20045245 A NO 20045245A NO 20045245 L NO20045245 L NO 20045245L
- Authority
- NO
- Norway
- Prior art keywords
- metabolite
- platelet aggregation
- ischemic
- valsartan
- acute
- Prior art date
Links
- 239000002207 metabolite Substances 0.000 title abstract 3
- 208000010110 spontaneous platelet aggregation Diseases 0.000 title abstract 3
- 239000004072 C09CA03 - Valsartan Substances 0.000 title abstract 2
- SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 title abstract 2
- 229960004699 valsartan Drugs 0.000 title abstract 2
- 230000000302 ischemic effect Effects 0.000 abstract 2
- 208000004476 Acute Coronary Syndrome Diseases 0.000 abstract 1
- 206010002383 Angina Pectoris Diseases 0.000 abstract 1
- 206010003178 Arterial thrombosis Diseases 0.000 abstract 1
- 206010008479 Chest Pain Diseases 0.000 abstract 1
- 206010051055 Deep vein thrombosis Diseases 0.000 abstract 1
- 206010019280 Heart failures Diseases 0.000 abstract 1
- 208000032382 Ischaemic stroke Diseases 0.000 abstract 1
- 208000018262 Peripheral vascular disease Diseases 0.000 abstract 1
- 206010038563 Reocclusion Diseases 0.000 abstract 1
- 208000032109 Transient ischaemic attack Diseases 0.000 abstract 1
- 206010047249 Venous thrombosis Diseases 0.000 abstract 1
- 230000001154 acute effect Effects 0.000 abstract 1
- 206010000891 acute myocardial infarction Diseases 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
- 230000001732 thrombotic effect Effects 0.000 abstract 1
- 201000010875 transient cerebral ischemia Diseases 0.000 abstract 1
- 125000003774 valeryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US38037302P | 2002-05-14 | 2002-05-14 | |
| US39501402P | 2002-07-11 | 2002-07-11 | |
| PCT/EP2003/004997 WO2003094915A1 (en) | 2002-05-14 | 2003-05-13 | Use of valsartan ot its metabolite to inhibit platelet aggregation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20045245L true NO20045245L (no) | 2004-11-30 |
Family
ID=29423705
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20045245A NO20045245L (no) | 2002-05-14 | 2004-11-30 | Anvendelse av valsartan eller dens metabolitt for a inhibere blodplateaggregering |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US20050197372A1 (de) |
| EP (1) | EP1505965B1 (de) |
| JP (1) | JP4467427B2 (de) |
| KR (1) | KR101005367B1 (de) |
| CN (1) | CN100408035C (de) |
| AT (1) | ATE334677T1 (de) |
| AU (1) | AU2003267447B8 (de) |
| BR (1) | BR0310018A (de) |
| CA (1) | CA2482541A1 (de) |
| CY (1) | CY1105638T1 (de) |
| DE (1) | DE60307265T2 (de) |
| DK (1) | DK1505965T3 (de) |
| ES (1) | ES2268403T3 (de) |
| HK (1) | HK1074395A1 (de) |
| IL (2) | IL164774A0 (de) |
| MX (1) | MXPA04011282A (de) |
| NO (1) | NO20045245L (de) |
| NZ (1) | NZ536295A (de) |
| PL (1) | PL371728A1 (de) |
| PT (1) | PT1505965E (de) |
| RU (1) | RU2334512C2 (de) |
| TW (1) | TWI299663B (de) |
| WO (1) | WO2003094915A1 (de) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20040265238A1 (en) * | 2003-06-27 | 2004-12-30 | Imtiaz Chaudry | Inhalable formulations for treating pulmonary hypertension and methods of using same |
| WO2005030202A1 (en) * | 2003-09-26 | 2005-04-07 | Novartis Ag | Use of angiotensin ii receptor antagonists for treating cerebrovascular disorders |
| AR057882A1 (es) | 2005-11-09 | 2007-12-26 | Novartis Ag | Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra |
| AR068814A1 (es) * | 2007-08-29 | 2009-12-09 | Orion Corp | Composicion farmaceutica que comprende levosimendan y un inhibidor de la enzima conversina de la angiotensina (ace), y uso |
| WO2015113001A1 (en) * | 2014-01-24 | 2015-07-30 | The Arizona Board Of Regents On Behalf Of The University Of Arizona | Materials, methods and devices for altering cell reactivity |
| CN110078640B (zh) * | 2019-03-29 | 2022-04-05 | 浙江美诺华药物化学有限公司 | 一种缬沙坦中间体的合成方法 |
| CN111643557B (zh) * | 2020-05-26 | 2022-02-22 | 四川省骨科医院 | 一种防治下肢深静脉血栓后遗症期的药物组合物及其制备方法和用途 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1994023638A2 (en) * | 1993-04-05 | 1994-10-27 | University Of Utah Research Foundation | Diagnosis and treatment of supravalvular aortic stenosis and williams syndrome |
| US6395728B2 (en) * | 1999-07-08 | 2002-05-28 | Novartis Ag | Method of treatment and pharmaceutical composition |
| AU6019700A (en) * | 1999-07-21 | 2001-02-05 | Takeda Chemical Industries Ltd. | Preventives for the recurrence of cerebrovascular failure and agents for ameliorating troubles following cerebrovascular failure and inhibiting progress thereof |
| WO2001082858A2 (de) * | 2000-05-04 | 2001-11-08 | Ipf Pharmaceuticals Gmbh | Neue verbindungen zur behandlung inflammatorischer und kardiovaskulärer erkrankungen |
| WO2001097805A2 (en) * | 2000-06-22 | 2001-12-27 | Novartis Ag | Solid valsartan pharmaceutical compositions |
-
2003
- 2003-05-12 TW TW092112854A patent/TWI299663B/zh not_active IP Right Cessation
- 2003-05-13 IL IL16477403A patent/IL164774A0/xx unknown
- 2003-05-13 CA CA002482541A patent/CA2482541A1/en not_active Abandoned
- 2003-05-13 PL PL03371728A patent/PL371728A1/xx unknown
- 2003-05-13 AT AT03749892T patent/ATE334677T1/de active
- 2003-05-13 DK DK03749892T patent/DK1505965T3/da active
- 2003-05-13 AU AU2003267447A patent/AU2003267447B8/en not_active Ceased
- 2003-05-13 BR BR0310018-9A patent/BR0310018A/pt not_active IP Right Cessation
- 2003-05-13 RU RU2004136583/15A patent/RU2334512C2/ru not_active IP Right Cessation
- 2003-05-13 WO PCT/EP2003/004997 patent/WO2003094915A1/en active IP Right Grant
- 2003-05-13 US US10/514,299 patent/US20050197372A1/en not_active Abandoned
- 2003-05-13 KR KR1020047018282A patent/KR101005367B1/ko not_active IP Right Cessation
- 2003-05-13 JP JP2004503001A patent/JP4467427B2/ja not_active Expired - Lifetime
- 2003-05-13 NZ NZ536295A patent/NZ536295A/en not_active IP Right Cessation
- 2003-05-13 CN CNB03810864XA patent/CN100408035C/zh not_active Expired - Fee Related
- 2003-05-13 EP EP03749892A patent/EP1505965B1/de not_active Expired - Lifetime
- 2003-05-13 ES ES03749892T patent/ES2268403T3/es not_active Expired - Lifetime
- 2003-05-13 DE DE60307265T patent/DE60307265T2/de not_active Expired - Lifetime
- 2003-05-13 MX MXPA04011282A patent/MXPA04011282A/es active IP Right Grant
- 2003-05-13 PT PT03749892T patent/PT1505965E/pt unknown
-
2004
- 2004-10-21 IL IL164774A patent/IL164774A/en not_active IP Right Cessation
- 2004-11-30 NO NO20045245A patent/NO20045245L/no not_active Application Discontinuation
-
2005
- 2005-07-21 HK HK05106187A patent/HK1074395A1/xx not_active IP Right Cessation
-
2006
- 2006-09-28 CY CY20061101409T patent/CY1105638T1/el unknown
-
2009
- 2009-02-02 US US12/363,926 patent/US20100048654A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| JP4467427B2 (ja) | 2010-05-26 |
| WO2003094915A1 (en) | 2003-11-20 |
| HK1074395A1 (en) | 2005-11-11 |
| EP1505965B1 (de) | 2006-08-02 |
| KR101005367B1 (ko) | 2010-12-30 |
| AU2003267447B8 (en) | 2009-08-06 |
| DE60307265T2 (de) | 2007-07-19 |
| NZ536295A (en) | 2006-12-22 |
| JP2005529913A (ja) | 2005-10-06 |
| TWI299663B (en) | 2008-08-11 |
| PL371728A1 (en) | 2005-06-27 |
| EP1505965A1 (de) | 2005-02-16 |
| AU2003267447B2 (en) | 2006-11-02 |
| IL164774A0 (en) | 2005-12-18 |
| MXPA04011282A (es) | 2005-01-25 |
| US20100048654A1 (en) | 2010-02-25 |
| CN100408035C (zh) | 2008-08-06 |
| US20050197372A1 (en) | 2005-09-08 |
| KR20050000532A (ko) | 2005-01-05 |
| TW200410686A (en) | 2004-07-01 |
| CA2482541A1 (en) | 2003-11-20 |
| PT1505965E (pt) | 2006-11-30 |
| ES2268403T3 (es) | 2007-03-16 |
| RU2004136583A (ru) | 2005-09-10 |
| CN1652774A (zh) | 2005-08-10 |
| IL164774A (en) | 2010-04-29 |
| BR0310018A (pt) | 2005-02-15 |
| AU2003267447A1 (en) | 2003-11-11 |
| ATE334677T1 (de) | 2006-08-15 |
| RU2334512C2 (ru) | 2008-09-27 |
| DE60307265D1 (de) | 2006-09-14 |
| CY1105638T1 (el) | 2010-12-22 |
| DK1505965T3 (da) | 2006-11-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1074395A1 (en) | Use of the metabolite of valsartan to inhibit platelet aggregation | |
| Fudim et al. | Role of volume redistribution in the congestion of heart failure | |
| Stamou et al. | Stroke after coronary artery bypass: incidence, predictors, and clinical outcome | |
| Sankaranarayanan et al. | How does chronic atrial fibrillation influence mortality in the modern treatment era? | |
| Izzo et al. | Mechanisms and management of hypertensive heart disease: from left ventricular hypertrophy to heart failure | |
| Scirica et al. | Effect of ranolazine, an antianginal agent with novel electrophysiological properties, on the incidence of arrhythmias in patients with non–ST-segment–elevation acute coronary syndrome: results from the Metabolic Efficiency with Ranolazine for Less Ischemia in Non–ST-Elevation Acute Coronary Syndrome–Thrombolysis in Myocardial Infarction 36 (MERLIN-TIMI 36) randomized controlled trial | |
| NO20081196L (no) | Terapeutisk middel for diabetes | |
| Bortolotti et al. | New tools for optimizing fluid resuscitation in acute pancreatitis | |
| Sun et al. | Early assistance with left ventricular assist device limits left ventricular remodeling after acute myocardial infarction in a swine model | |
| Pandey et al. | Acute influenza infection presenting with cardiac tamponade: a case report and review of literature | |
| Niehues et al. | Incidence and predictors of cardiac arrhythmias in patients with COVID-19 induced ARDS | |
| RU2011138955A (ru) | Производные 1, 4-бензотиазепин-1-оксида и фармацевтическая композиция с использованием таких соединений | |
| Khouri et al. | What is the ideal blood pressure goal for patients with stage III or higher chronic kidney disease? | |
| Alkar et al. | Ischemic Cardiomyopathy: Contemporary Clinical Management | |
| Valentijn et al. | Influence of aortic valve calcium on outcome in patients undergoing peripheral vascular surgery | |
| Aronow | Editorials Editorial on management of diabetes mellitus with coronary artery disease | |
| Sadeghian et al. | Two ecstasy-induced myocardial infarctions during a three month period in a young man | |
| Rosano | Cardiovascular pharmacotherapy a growing sub-speciality across all areas of cardiology: a European tradition | |
| NO20071107L (no) | 1,1,2,2-tetra(hetero)aryletaner eller 1,1,2-tri(hetero)aryl-2-heterosyklyletaner som kaliumkanalinhibitorer | |
| Blackburn | Actions of Drugs on the Cardiovascular and Renal System | |
| Biviano et al. | The Use of Ranolazine in the Management of Recurrent Atrial Fibrillation After Percutaneous Radiofrequency Ablation. | |
| Pericleous | Type II heparin-induced thrombocytopenia in an elderly patient: case report | |
| TH137265A (th) | วิธีการสำหรับเพิ่มความคงตัวของแฟคเตอร์-1 แอลฟา (factor-1 alpha) ที่เหนี่ยวนำ ด้วยภาวะเลือดที่มีออกซิเจนน้อย | |
| WO2014027262A3 (en) | Compositions and methods for the treatment angina and cardiovascular conditions | |
| NZ731416B2 (en) | Pyrimidinones as factor xia inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |